BlackRock Inc. increased its stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 1.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,248,803 shares of the specialty pharmaceutical company’s stock after acquiring an additional 16,405 shares during the quarter. BlackRock Inc. owned about 0.08% of Eagle Pharmaceuticals worth $65,800,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the stock. Northern Trust Corp lifted its stake in shares of Eagle Pharmaceuticals by 4.3% in the first quarter. Northern Trust Corp now owns 133,798 shares of the specialty pharmaceutical company’s stock worth $7,049,000 after acquiring an additional 5,495 shares during the period. O Shaughnessy Asset Management LLC lifted its stake in shares of Eagle Pharmaceuticals by 28,468.8% in the first quarter. O Shaughnessy Asset Management LLC now owns 4,571 shares of the specialty pharmaceutical company’s stock worth $241,000 after acquiring an additional 4,555 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Eagle Pharmaceuticals by 29.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 87,125 shares of the specialty pharmaceutical company’s stock worth $4,591,000 after acquiring an additional 20,031 shares during the period. LSV Asset Management lifted its stake in shares of Eagle Pharmaceuticals by 17.1% in the first quarter. LSV Asset Management now owns 859,142 shares of the specialty pharmaceutical company’s stock worth $45,268,000 after acquiring an additional 125,320 shares during the period. Finally, Virginia Retirement Systems ET AL acquired a new position in shares of Eagle Pharmaceuticals in the first quarter worth approximately $632,000.
A number of research firms recently commented on EGRX. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 13th. $1 lifted their price objective on Eagle Pharmaceuticals to $119.00 and gave the stock a “buy” rating in a research note on Tuesday. Mizuho raised Eagle Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Monday, June 11th. Cantor Fitzgerald assumed coverage on Eagle Pharmaceuticals in a report on Monday, June 11th. They issued an “overweight” rating and a $81.00 target price for the company. Finally, BidaskClub upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $80.80.
Shares of EGRX stock opened at $76.53 on Friday. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of 22.71 and a beta of 1.47. The company has a quick ratio of 5.66, a current ratio of 5.87 and a debt-to-equity ratio of 0.23. Eagle Pharmaceuticals Inc has a fifty-two week low of $45.05 and a fifty-two week high of $83.47.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported $0.53 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.68 by ($0.15). The business had revenue of $46.60 million during the quarter, compared to the consensus estimate of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The company’s revenue for the quarter was down 39.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.42 earnings per share. research analysts anticipate that Eagle Pharmaceuticals Inc will post 1.92 earnings per share for the current year.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.